獸醫腫瘤市場規模、佔有率和成長分析（按治療類型、動物類型、癌症類型、最終用戶和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，獸醫腫瘤市場規模將達到 2907.9 億美元，到 2025 年將成長至 3,259.7 億美元，到 2033 年將成長至 8,128.8 億美元，在預測期（2026-2033 年）內複合年成長率為 12.1%。

由於寵物癌症發生率的上升以及對獸醫腫瘤治療需求的成長，獸醫腫瘤市場正經歷顯著成長。在獸醫腫瘤治療水準不斷提高的推動下，寵物飼主加大了對寵物醫療保健的投入。已開發國家的獸醫醫療費用持續上漲，寵物腫瘤疾病的普遍性凸顯了改善腫瘤治療的緊迫性。此外，評估腫瘤治療的獸醫臨床試驗數量的增加也推動了市場擴張，而諸如美國獸醫協會（AVMA）動物健康研究資料庫等資源則為研究活動提供了支持。寵物擬人化的趨勢加深了飼主與寵物之間的情感紐帶，導致寵物飼養量和醫療保健支出增加，最終推動了獸醫腫瘤市場的發展。

獸醫腫瘤市場促進因素

伴侶動物（尤其是犬貓）癌症發生率的不斷上升是推動獸醫腫瘤市場發展的主要因素。隨著寵物壽命的延長，它們和人類一樣，更容易患上各種疾病，包括癌症。這一趨勢促使人們對先進且有效的腫瘤治療方法的需求日益成長。因此，寵物飼主越來越傾向於尋求專業的獸醫護理，這進一步推動了腫瘤領域服務和產品的需求。人們對寵物健康的日益關注以及他們為此投入的意願，都在支持獸醫腫瘤市場的擴張和發展。

獸醫腫瘤市場限制因素

獸醫腫瘤市場面臨的主要挑戰之一是癌症治療的高昂費用，這對飼主來說可能是一個巨大的障礙。這些治療通常涉及多種服務，包括診斷測試、手術、藥物和持續的後續觀察，所有這些都可能造成沉重的經濟負擔。因此，這些必要服務的高昂費用限制了獸醫腫瘤治療的可及性和可負擔性，最終影響飼主在需要時為他們心愛的寵物所做的選擇。這種經濟限制是該產業面臨的一個突出挑戰。

獸醫腫瘤市場趨勢

與人類腫瘤學的發展趨勢類似，獸醫腫瘤學市場正經歷著向個人化醫療的重大轉變。這種新的關注點優先考慮根據每隻動物的癌症特異性基因特徵和生物標記物譜量身定做的個人化治療方案。透過利用基因組學和診斷技術的進步，獸醫腫瘤學家能夠在提高治療效果的同時減少副作用，最終改善患者的預後。這種個人化方法不僅能夠實現更精準的治療策略，還能滿足飼主對其愛寵日益成長的高品質、個人化照護的期望，從而進一步推動獸醫腫瘤學領域的創新和投資。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究

全球獸醫腫瘤市場規模（按治療類型和複合年成長率分類）（2026-2033 年）

• 化療
  • 口服化療
  • 注射化療
• 放射線治療
  • 體外放射線治療
  • 體內放射療法
• 免疫療法
  • 單株抗體
  • 癌症疫苗
• 外科手術
  • 腫瘤切除
  • 重組手術

全球獸醫腫瘤市場規模（依動物類型分類）及複合年成長率（2026-2033 年）

• 伴侶動物
  • 狗
  • 貓
• 家畜
  • 牛
  • 羊
  • 豬

全球獸醫腫瘤市場規模（按癌症類型和複合年成長率分類）（2026-2033 年）

• 淋巴瘤
• 肥大細胞瘤
• 黑色素瘤
• 乳腺腺癌和鱗狀細胞癌
• 其他

全球獸醫腫瘤市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 獸醫診所
• 動物診所
• 研究所
• 其他

全球獸醫腫瘤市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• Zoetis Inc.（USA）
• Elanco Animal Health（USA）
• Boehringer Ingelheim（Germany）
• Merck Animal Health（USA）
• Virbac（France）
• Ceva Sante Animale（France）
• Vetoquinol（France）
• Dechra Pharmaceuticals（UK）
• IDEXX Laboratories（USA）
• Heska Corporation（USA）
• Aratana Therapeutics（USA）
• Karyopharm Therapeutics（USA）
• Regeneus Ltd.（Australia）
• PetCure Oncology（USA）
• Accuray Incorporated（USA）
• Varian Medical Systems（USA）
• Morphogenesis, Inc.（USA）
• Nippon Zenyaku Kogyo Co., Ltd.（Japan）
• Eli Lilly and Company（USA）
• Bayer AG（Germany）

結論與建議

Veterinary Oncology Market size was valued at USD 290.79 Billion in 2024 and is poised to grow from USD 325.97 Billion in 2025 to USD 812.88 Billion by 2033, growing at a CAGR of 12.1% during the forecast period (2026-2033).

Veterinary oncology is experiencing significant market growth driven by an increase in cancer incidence among pets and a heightened demand for veterinary cancer treatments. Pet owners are increasingly investing in animal healthcare, fueled by initiatives aimed at improving veterinary oncology. In developed countries, spending on animal healthcare is on the rise, and the prevalence of neoplastic diseases in pets underlines the urgent need for better oncology treatments. Additionally, an upswing in veterinary clinical trials evaluating oncologic therapies further supports market expansion, with resources like the AVMA Animal Health Research Database aiding research efforts. The pet humanization trend is promoting closer bonds between owners and their pets, leading to increased pet adoption and healthcare spending, ultimately boosting the veterinary oncology market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Veterinary Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Veterinary Oncology Market Segments Analysis

Global Veterinary Oncology Market is segmented by therapy type, animal type, cancer type, end-user and region. Based on therapy type, the market is segmented into chemotherapy, radiation therapy, immunotherapy and surgery. Based on animal type, the market is segmented into companion animals and livestock animals. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer and others. Based on end-user, the market is segmented into veterinary hospitals, veterinary clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Veterinary Oncology Market

The increasing occurrence of cancer among companion animals, particularly dogs and cats, significantly propels the veterinary oncology market. As pets enjoy longer lifespans, they become more vulnerable to various health issues, including cancer, similar to humans. This trend creates a growing need for advanced and effective oncology treatments to address these conditions. Consequently, pet owners are more inclined to seek specialized veterinary care, further fueling the demand for services and products within the oncology sector. This heightened awareness around pet health and the willingness to invest in their well-being underscores the expansion and evolution of the veterinary oncology market.

Restraints in the Veterinary Oncology Market

One of the primary challenges facing the veterinary oncology market is the substantial expense associated with cancer treatments, which can present a significant barrier for pet owners. These treatments often encompass a range of services, including diagnostic testing, surgical procedures, medication, and ongoing follow-up care, all of which can accumulate into a considerable financial burden. As a result, the high costs associated with these essential services can restrict the accessibility and affordability of veterinary oncology, ultimately impacting the choices pet owners can make for their beloved animals in times of need. This financial constraint is a prominent issue in the industry.

Market Trends of the Veterinary Oncology Market

The veterinary oncology market is witnessing a significant shift towards personalized medicine, akin to trends in human oncology. This emerging focus prioritizes individualized treatment plans that align with the unique genetic characteristics and biomarker profiles of each animal's cancer. By leveraging advancements in genomics and diagnostics, veterinary oncologists can enhance therapeutic efficacy while reducing adverse effects, ultimately leading to improved patient outcomes. This tailored approach not only fosters a more precise treatment strategy but also aligns with pet owners' increasing expectations for high-quality, customized care for their beloved animals, driving further innovation and investment in the veterinary oncology sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Veterinary Oncology Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
  • Oral Chemotherapy
  • Injectable Chemotherapy
• Radiation Therapy
  • External Beam Radiation Therapy
  • Internal Radiation Therapy
• Immunotherapy
  • Monoclonal Antibodies
  • Cancer Vaccines
• Surgery
  • Tumor Removal
  • Reconstructive Surgery

Global Veterinary Oncology Market Size by Animal Type & CAGR (2026-2033)

• Market Overview
• Companion Animals
  • Dogs
  • Cats
• Livestock Animals
  • Cattle
  • Sheep
  • Pigs

Global Veterinary Oncology Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Lymphoma
• Mast Cell Cancer
• Melanoma
• Mammary And Squamous Cell Cancer
• Others

Global Veterinary Oncology Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Veterinary Hospitals
• Veterinary Clinics
• Research Institutes
• Others

Global Veterinary Oncology Market Size & CAGR (2026-2033)

• North America (Therapy Type, Animal Type, Cancer Type, End-User)
  • US
  • Canada
• Europe (Therapy Type, Animal Type, Cancer Type, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Animal Type, Cancer Type, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Animal Type, Cancer Type, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Animal Type, Cancer Type, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Zoetis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heska Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aratana Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneus Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accuray Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Varian Medical Systems (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Morphogenesis, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nippon Zenyaku Kogyo Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations